Transcenta Holding Limited
HKEX:6628.HK
1.04 (HKD) • At close September 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Transcenta Holding Limited |
Symbool | 6628.HK |
Munteenheid | HKD |
Prijs | 1.04 |
Beurswaarde | 456,648,481 |
Dividendpercentage | 0% |
52-weken bereik | 0.93 - 4.08 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Xueming Qian Ph.D. |
Website | https://www.transcenta.com |
An error occurred while fetching data.
Over Transcenta Holding Limited
Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs in the People's Republic of China and the United States. The company develops MSB2311, a humanized PD-L1 monoclonal antibody (mAb) candidate for TMB-H solid tumors; TST001, a humanized claudin 18.2
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (HKD)
Cijfers zijn in miljoenen (HKD)